Scotti, Andrea; Coisne, Augustin; Taramasso, Maurizio; Granada, Juan F; Ludwig, Sebastian; Rodés-Cabau, Josep; Lurz, Philipp; Hausleiter, Jörg; Fam, Neil; Kodali, Susheel K; Rosiene, Joel; Feinberg, Ari; Pozzoli, Alberto; Alessandrini, Hannes; Biasco, Luigi; Brochet, Eric; Denti, Paolo; Estevez-Loureiro, Rodrigo; Frerker, Christian; Ho, Edwin C; ... (2023). Sex-Related Characteristics and Short-Term Outcomes of Patients Undergoing Transcatheter Tricuspid Valve Intervention for Tricuspid Regurgitation. European Heart Journal, 44(10), pp. 822-832. Oxford University Press 10.1093/eurheartj/ehac735
|
Text
ehac735.pdf - Accepted Version Available under License Publisher holds Copyright. Download (1MB) | Preview |
BACKGROUND AND AIMS
The impact of sex in patients with significant tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve intervention (TTVI) is unknown. The aim of this study was to investigate sex-specific outcomes in patients with significant TR treated with TTVI versus medical therapy alone.
METHODS
The TriValve (Transcatheter Tricuspid Valve Therapies) registry collected patients with significant TR from 24 centers who underwent TTVI from 2016 to 2021. A control cohort was formed by medically managed patients with ≥ severe isolated TR diagnosed in 2015-2018. Primary endpoint was freedom from all-cause mortality. Secondary endpoints were heart failure (HF) hospitalization, New York Heart Association (NYHA) functional status, and TR severity. One-year outcomes were assessed for the TriValve cohort and compared with the control cohort with the inverse probability of treatment weighting (IPTW).
RESULTS
A total of 556 and 2072 patients were included from the TriValve and control groups, respectively. After TTVI, there was no difference between women and men in 1-year freedom from all-cause mortality (80.9% vs. 77.9%, p = 0.56, nor in HF hospitalization (p = 0.36), NYHA functional class III-IV (p = 0.17), and TR severity >2 + at last follow-up (p = 0.42). Multivariable Cox-regression weighted by IPTW showed an improved 1-year survival after TTVI compared to medical therapy alone in both women (adjusted hazard ratio [HR] 0.45, 95% confidence interval [CI] 0.23-0.83, p = 0.01) and men (adjusted HR 0.42, 95% CI 0.18-0.89, p = 0.03).
CONCLUSIONS
After TTVI in high-risk patients, there were no sex-related differences in terms of survival, HF hospitalization, functional status, and TR reduction up to 1 year. The IPTW analysis shows a survival benefit of TTVI over medical therapy alone in both women and men.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology |
UniBE Contributor: |
Praz, Fabien Daniel, Wild, Mirjam Gauri, Windecker, Stephan |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0195-668X |
Publisher: |
Oxford University Press |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
30 Nov 2022 10:18 |
Last Modified: |
30 Nov 2023 00:25 |
Publisher DOI: |
10.1093/eurheartj/ehac735 |
PubMed ID: |
36445158 |
Uncontrolled Keywords: |
sex transcatheter tricuspid valve intervention tricuspid regurgitation |
BORIS DOI: |
10.48350/175331 |
URI: |
https://boris.unibe.ch/id/eprint/175331 |
Actions (login required)
 |
Edit item |